摘要
Objective: To characterize the relationship of new eosinophilic folliculitis (EF) cases between June 30, 1994, and January 5, 2000, and antiretroviral therapy (ART) status and immune reconstitution. Design: Retrospective cohort analysis. Setting: Dermatology clinics at a county hospital. Subjects: Fifty-seven consec utive subjects with biopsy-proved EF from the pathology database. Subject group s were as follows: native to ART, receiving ART without protease inhibitors/ non nucleoside reverse transcriptase inhibitors, and receiving ART containing protea se inhibitors/nonnucleoside reverse transcriptase inhibitors. Main Outcome Measu res: Onset of EF, CD4 cell count and nadir at EF onset, and time of ART initiati on. Results: Among the 3 groups previously described, mean CD4 cell counts (86.2 6/μL vs 113.82/μL vs 145.65/μL, respectively [Kruskal-Wallis rank sumtest, P=.15]) and nadir (68.43/μL vs 66.18/μL vs 64.17/μL, respectively [Kruskal-Wallis rank sum test, P=.41]) at EF diagnosis were not statistically different. Fifty-two subjects (91%), regardless of treatment group, had a nadir below 200/ μL. Of the subjects undergoing ART, 28 (82%) developed EF within 6 months of i nitiating ART; their average CD4 cell count increase was 108/μL. Of the 23 subj ects receiving protease inhibitor/nonnucleoside reverse transcriptase inhibitor -containing ART regimens, 17 (74%) were diagnosed as having EF within 3 months , with 4 additional subjects diagnosed as having EF within 6 months (a total of 21 [91%] of the 23 subjects). This is not significantly different from the 7 (64%) of 11 subjects diagnosed as having EF at 3 and 6 months of starting ART wit hout protease inhibitors/nonnucleoside reverse transcriptase inhibitors (P=.07) (odds ratio, 0.18; 95%confidence interval, 0.01-1.54). Conclusions: Our study shows an association between low nadir (66.28/μL) and low CD4 cell count (115.5 4/μL) and the development of EF, regardless of subjects’ART status. However, m ost subjects receiving ART were diagnosed as having EF within 3 to 6 months of A RT initiation, regardless of the
Objective: To characterize the relationship of new eosinophilic folliculitis (EF) cases between June 30, 1994, and January 5, 2000, and antiretroviral therapy (ART) status and immune reconstitution. Design: Retrospective cohort analysis. Setting: Dermatology clinics at a county hospital. Subjects: Fifty-seven consec utive subjects with biopsy-proved EF from the pathology database. Subject group s were as follows: native to ART, receiving ART without protease inhibitors/ non nucleoside reverse transcriptase inhibitors, and receiving ART containing protea se inhibitors/nonnucleoside reverse transcriptase inhibitors. Main Outcome Measu res: Onset of EF, CD4 cell count and nadir at EF onset, and time of ART initiati on. Results: Among the 3 groups previously described, mean CD4 cell counts (86.2 6/μL vs 113.82/μL vs 145.65/μL, respectively [Kruskal-Wallis rank sumtest, P=.15]) and nadir (68.43/μL vs 66.18/μL vs 64.17/μL, respectively [Kruskal-Wallis rank sum test, P=.41]) at EF diagnosis were not statistically different. Fifty-two subjects (91%), regardless of treatment group, had a nadir below 200/ μL. Of the subjects undergoing ART, 28 (82%) developed EF within 6 months of i nitiating ART; their average CD4 cell count increase was 108/μL. Of the 23 subj ects receiving protease inhibitor/nonnucleoside reverse transcriptase inhibitor -containing ART regimens, 17 (74%) were diagnosed as having EF within 3 months , with 4 additional subjects diagnosed as having EF within 6 months (a total of 21 [91%] of the 23 subjects). This is not significantly different from the 7 (64%) of 11 subjects diagnosed as having EF at 3 and 6 months of starting ART wit hout protease inhibitors/nonnucleoside reverse transcriptase inhibitors (P=.07) (odds ratio, 0.18; 95%confidence interval, 0.01-1.54). Conclusions: Our study shows an association between low nadir (66.28/μL) and low CD4 cell count (115.5 4/μL) and the development of EF, regardless of subjects'ART status. However, m ost subjects receiving ART were diagnosed as having EF within 3 to 6 months of A RT initiation, regardless of the regimen
